• 2022-06
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2018-07
  • br In summary our results suggest that


    In summary, our results suggest that combined-radiotherapy and systemic chemotherapy offers excellent outcomes for patients with all subtypes of stage IIIC endometrial cancer. For patients with low-grade endometrioid histology, radiotherapy alone may be sufficient, especially for patients at high risk for toxicity from multimodality treatment.
    Supplementary data to this article can be found online at https://doi.
    Conflict of interest
    This study was supported in part by the National Institute of Cancer, National Institutes of Health through Cancer Center Support Grant P30 CA016672 and SPORE for Uterine Cancer 2P50 CA098258-13. SNW is supported by the Andrew Sabin Family Fellowship.
    Author contributions
    Study design: all authors; Data collection: BVC, CWS, VP, PJE, and
    AHK; Statistical analysis: BVC, MSN and PKA; Manuscript writing: BVC
    and AHK; Interpretation of data and manuscript review: all authors.
    The authors thank Dr. Amy Ninetto of the Department of Scientific Publications at MD Anderson Cancer Center for her valuable assistance in editing the manuscript.
    [8] D. Matei, V.L. Filiaci, M. Randall, M. Steinhoff, P. DiSilvestro, K.M. Moxley, et al., A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma, J. Clin. Oncol. 35 (2017) 5505. [9] S.M. de Boer, M.E. Powell, L. Mileshkin, D. Katsaros, P. Bessette, C. Haie-Meder, et al., Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial, Lancet Oncol. 19 (2018) 295–309. 
    [10] M. Randall, V. Filiaci, D. McMeekin, C.M. Yashar, R. Mannel, R. Salani, et al., A phase 3 trial of pelvic Necrosulfonamide therapy versus vaginal cuff brachytherapy followed by pac-litaxel/carboplatin chemotherapy in patients with high-risk, early-stage endome-trial cancer: a Gynecology Oncology Group Study, Int. J. Radiat. Oncol. Biol. Phys. 99 (2017) 1313.
    [12] A. Klopp, B.D. Smith, K. Alektiar, A. Cabrera, A.L. Damato, B. Erickson, et al., The role of postoperative radiation therapy for endometrial cancer: executive summary of an American Society for Radiation Oncology evidence-based guideline, Pract. Radiat. Oncol. 4 (2014) 137–144.
    [13] L.A. Meyer, K. Bohlke, M.A. Powell, A.N. Fader, G.E. Franklin, L.J. Lee, et al., Postoper-ative radiation therapy for endometrial cancer: American Society of Clinical Oncol-ogy clinical practice guideline endorsement of the American Society for Radiation Oncology evidence-based guideline, J. Clin. Oncol. 33 (2015) 2908–2913.
    [18] A.A. Secord, L.J. Havrilesky, D.M. O'Malley, V. Bae-Jump, N.D. Fleming, G. Broadwater, et al., A multicenter evaluation of sequential multimodality therapy and clinical out-come for the treatment of advanced endometrial cancer, Gynecol. Oncol. 114 (2009) 442–447.
    [20] K. Greven, K. Winter, K. Underhill, J. Fontenesci, J. Cooper, T. Burke, Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer, Gynecol. Oncol. 103 (2006) 155–159.
    Contents lists available at ScienceDirect
    Gynecologic Oncology
    Adjuvant therapy in stage III endometrial cancer confined to the pelvis
    Reem Albeesh a, Guy-Anne Turgeon a, Joanne Alfieri a, José João Mansure b, Lili Fu c, Jocelyne Arseneau c, Xing Zeng d, Kris Jardon d, Lucy Gilbert d, Luis Souhami a,
    a Department of Radiation Oncology, McGill University Health Centre, Cedars Cancer Centre, Canada
    b Oncology Research Unit, McGill University Health Centre, Cedars Cancer Centre, Canada
    c Department of Pathology, McGill University Health Centre, Cedars Cancer Centre, Canada